<DOC>
	<DOCNO>NCT00044746</DOCNO>
	<brief_summary>Phase IV Open-Label Foot Infection Study conduct generate comparative Efficacy Safety data Diabetic Inpatients .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Piperacillin/Tazobactam Ampicillin/Sulbactam Patients With Diabetic Foot Infections</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients diabetes mellitus Inpatient Have 1 infect ulcer ( ) ankle Exclusion Criteria Must gangrene severely impaired arterial supply foot Must bone infection area ulcer Must allergy penicillin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Diabetes</keyword>
</DOC>